tbuckley/cabot-search huggingface dataset:
Combination therapy with pegylated liposomal doxorubicin and carboplatin in malignant gynecologic tumors. A prospective multicenter phase II trial of the AGO-OVAR and the AGO Kommission Uterus (AGO-K-Ut)
Authors: F. Hilpert, S. Loibl, J. Huober, P. Wimberger, A. Staehle, C. Jackisch, K. Wollschlaeger, H. Koelbl, M. Beckmann, A. Du Bois
Journal: Journal of Clinical Oncology (2006)

5095 Background: To determine the toxicity and efficacy of combination therapy with pegylated liposomal doxorubicin (PLD) and carboplatin in patients with malignant gynecologic tumors. Methods: Patients with recurrent or advanced uterine sarcomas, endometrial, cervical or vaginal cancer or with recurrent platinum-sensitive ovarian cancer were treated with PLD 40mg/m 2 and carboplatin AUC 6, q28 over 6 cycles (up to 10 cycles allowed). Primary and secondary endpoints were tolerability and efficacy. Efficacy was measured according to RECIST and/or CA-125 GCIG criteria. Results: 67 pts with recurrent ovarian cancer, 11 pts with uterine sarcomas, 31 pts with endometrial cancer and 31 pts with cervical or vaginal cancer have been recruited (total 140 pts, 87 pts evaluable for response). Grade 3/4 hematologic toxicities occured in 8% for anemia, 14% for thrombocytopenia, 23% for leukopenia, and 25% for neutropenia of whom 2% developed febrile neutropenia. Non-hematologic Grade 3/4 toxicities have been observed in more than 5% of all patients for the following items: asthenia (14%), pain (10%), dyspnea (9%), palmo-plantar-erythema (7%), nausea and vomiting (7%), diarrhea (5%). The median dose intensity was 94% for PLD and 97% for carboplatin. 76% of all non-progressing patients received at least 5 cycles. The overall response rate was 56% in ovarian cancer, 43% in uterine sarcomas, 44% in endometrial cancer, and 14% in cervical and vaginal cancer. Conclusions: PLD/carboplatin was well tolerated, even in pretreated patients. The combination showed remarkable efficacy in patients with uterine sarcomas, endometrial cancer, and ovarian cancer which merits further evaluation. CA 125 response criteria in ovarian cancer are under evaluation and will be presented on ASCO. However, the regimen had limited efficacy in cervical and vaginal cancer. A prospective randomized trial in recurrent ovarian cancer patients comparing carboplatin/PLD with paclitaxel/carboplatin has already been started within the international study group network (AGO-OVAR 2.9; CALYPSO-trial). [Table: see text]
THREE THUMBS, BICUSPID AORTIC VALVE, BOVINE AORTIC ARCH AND SPONTANEOUS CORONARY ARTERY DISSECTION (SCAD) ALONG WITH FIBROMUSCULAR DYSPLASIA (FMD) IN A PATIENT WITH PRESUMPTIVE DUANE RADIAL RAY SYNDROME
Authors: Ahmed Nagy, Nouran Sorour, Ely Gracia, Craig Smith, Alvaro Alonso, Colleen Harrington
Journal: Journal of the American College of Cardiology (2020)
Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
Authors: Tetsu Kobayashi, Osamu Hataji, Hajime Fujimoto, Corina D’Alessandro-Gabazza, Taro Yasuma, Esteban C. Gabazza
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
Patterns of pharmaceutical therapy in advanced melanoma.
Authors: Aikaterini Bilitou, Zhongyun Zhao, Beth L. Barber, Genevieve Sian Clapton, Deborah Saltman
Journal: Journal of Clinical Oncology (2013)

e20014 Background: Since 2011, two therapies that provide novel approaches to the treatment of advanced (unresectable or metastatic) melanoma have been introduced to the market: ipilimumab for second line and vemurafenib for BRAF mutation-positive melanoma. It is not known how the new drugs influence treatment; this study investigated current treatment patterns in advanced melanoma. Methods: A clinician-validated, web-based survey was administered between August and November 2012 to clinicians who treat advanced melanoma in France, Germany, Italy, Spain, and the UK. Respondents were asked about their treatment of patients in the previous 12 months, including treatment modalities and pharmaceutical therapies used, and factors that affect treatment choice. Results: 150 oncologists and dermatologists completed the survey, 30 in each country. Pharmaceutical therapy was more commonly used than other treatment modalities and varied by stage of disease. A high proportion of patients with late stage of disease were treated with pharmaceutical therapy in Germany (85% in M1B) and France (83% in M1C). Among the countries, 51% (Italy) to 87% (France) of respondents test BRAF mutation status. In patients with wild-type BRAF tumors, dacarbazine, which has not been shown to provide any overall survival benefit, was the most commonly used drug for first-line therapy in all countries. In mutated BRAF tumors, vemurafenib was the most commonly used drug in first line therapy in 3 of 5 countries. There was no standard of care in second line for either patients with wild-type or mutated-BRAFtumors; therapies used included fotemustine, temozolomide, interferon, paclitaxel, and ipilimumab. Conclusions: Treatment options for patients with advanced melanoma are limited, particularly for patients with wild-type BRAF disease. In second line, there does not appear to be an established standard of care: a range of treatments are used, including several not indicated for melanoma.
Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for gefitinib sensitivity in Japanese patients with non-small cell lung cancer
Authors: K. Hotta, K. Kiura, M. Tabata, N. Takigawa, Y. Fujiwara, S. Umemura, S. Hosokawa, A. Hisamoto, H. Ueoka, M. Tanimoto
Journal: Journal of Clinical Oncology (2006)

17029 Background: The aim was to evaluate the utility of an early change in CEA levels for predicting subsequent gefitinib sensitivity in NSCLC patients. Methods: CEA level was measured before and after the beginning of gefitinib treatment (day1) in 110 (91%) of consecutive 121 patients. Daily decline rate of CEA was simply defined for each patient as follows: (M 0 −Mx)/Dx/M 0 *100(%), with the baseline level (M 0 ), the level on days × (Mx), and days from day 1 to day X (Dx). Results: Patient characteristics were as follows; median age: 62, M/F: 61/39%, Ad/others: 84/16% and smoker: 66%. Objective response rate and disease control rate were 28.2% and 74.5%, respectively. Median baseline CEA level was 12.6 ng/mL. Daily decline rate of CEA level from day 1 to the date on which confirmation of objective response was performed significantly differed among the response categories; median decreases in percentages were 0.86, 0.06, and −1.52%/day in CR/PR, SD, and PD patients, respectively (p &lt; 0.0001). This association was more evident in the 70 patients with abnormal baseline CEA level (≥5.0 ng/mL). A cutoff level of −0.58% decrease per day most accurately reflected tumor shrinkage in the 70 patients, with sensitivity, specificity, and positive and negative predictive values for disease control (CR/PR/SD) of 89.1, 73.3, 92.5 and 64.7%, respectively. Among 49 (41%) patients reassessed CEA levels within the first 2 weeks since day 1, 41 could continue the treatment without any disease progression during this period. The daily decline rate in this early phase tended to differ between the responses (median; 1.57 and −0.50% in CR/PR/SD and PD, respectively; p = 0.0975), and less exactly reflected disease control with sensitivity, specificity, and positive and negative predictive values of 82.1, 40.0, 88.5, and 28.6%, respectively when a cutoff of −0.58% was applied. Conclusion: Degree of change in CEA level from the start of gefitinib treatment to confirmation of objective response significantly correlated with tumor shrinkage. As a predictor for obtaining disease control, monitoring early change in CEA level might be useful due to high sensitivity and positive predictive value, in spite of low specificity for detection of PD patients. No significant financial relationships to disclose.
Incidence and outcomes of chronic myeloid leukemia (CML) patients (pts) treated with second-generation tyrosine kinase inhibitors (TKI) who develop other chromosomal abnormalities (OCA).
Authors: Naveen Pemmaraju, Hagop M. Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, Gautam Borthakur, Elizabeth M Burton, Sara Dellasala, Sherry Pierce, Steven Mitchell Kornblau, Srdan Verstovsek, Susan Mary O'Brien, Jorge E. Cortes
Journal: Journal of Clinical Oncology (2013)

7090 Background: Development of OCA has been reported among pts receiving imatinib as initial therapy for CML. Little is known about OCA development in CML pts treated with frontline 2nd generation TKI (dasatinib, nilotinib). Methods: OCA is defined as cytogenetic abnormality in non-Philadelphia chromosome positive clones as pts respond to TKI. Among pts treated with frontline dasatinib (n=99) or nilotinib (n=117), on parallel prospective single-arm phase II protocols at MDACC, 30 OCA ptswere identified, chronic (n=25) or accelerated phase (AP) (n=5). Results: 11 (11%) pts treated with dasatinib and 19 (16%) with nilotinib developed OCA; median follow-up 30 mo (range 0-71). Difference in OCA incidence with dasatinib and nilotinib was not statistically significant. At start of therapy, median age (years) of OCA pts was 53 (41-71) with dasatinib and 52 (37-82) with nilotinib, compared to those pts without OCA: 48 (18-83) with dasatinib and 49 (17-87) with nilotinib. Most common OCA was abnormality of chromosome 7 with 6 occurrences in 5 pts (1 pt with both inv(7) and +7) (inversion (n=1), 2 different translocations (n=2), deletions (n=2), and additions (n=1)). No pts developed trisomy 8 (historically most common OCA in imatinib-treated pts). Median time to first OCA: 9 mo (range 3-58) for all pts (12 mo (range 3-58) for dasatinib group and 9 mo (3-48) for nilotinib group). OCA disappeared spontaneously in 25 pts during follow-up. Outcomes for OCA versus non-OCA group (Table). For AP pts: 3/6 (50%) in dasatinib group and 2/17 (12%) in nilotinib group developed OCA. None of the OCA pts has developed AML or MDS. Conclusions: OCA is observed in 10-15% of pts receiving initial therapy with 2nd generation TKI. At median follow-up of 30 mo, occurrence of OCA confers no adverse impact on outcomes when compared to non-OCA pts treated with 2nd generation TKI and has not resulted in other hematologic disorders. [Table: see text]
Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Heather A. Parsons, Justin Rhoades, Sarah C. Reed, Gregory Gydush, Priyanka Ram, Pedro Exman, Kan Xiong, Christopher C. Lo, Tianyu Li, Mark Fleharty, Gregory J. Kirkner, Denisse Rotem, Ofir Cohen, Fangyan Yu, Mariana Fitarelli-Kiehl, Ka Wai Leong, Melissa E. Hughes, Shoshana M. Rosenberg, Laura C. Collins, Kathy D. Miller, Brendan Blumenstiel, Lorenzo Trippa, Carrie Cibulskis, Donna S. Neuberg, Matthew DeFelice, Samuel S. Freeman, Niall J. Lennon, Nikhil Wagle, Gavin Ha, Daniel G. Stover, Atish D. Choudhury, Gad Getz, Eric P. Winer, Matthew Meyerson, Nancy U. Lin, Ian Krop, J. Christopher Love, G. Mike Makrigiorgos, Ann H. Partridge, Erica L. Mayer, Todd R. Golub, Viktor A. Adalsteinsson
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Existing cell-free DNA (cfDNA) methods lack the sensitivity needed for detecting minimal residual disease (MRD) following therapy. We developed a test for tracking hundreds of patient-specific mutations to detect MRD with a 1,000-fold lower error rate than conventional sequencing. Experimental Design: We compared the sensitivity of our approach to digital droplet PCR (ddPCR) in a dilution series, then retrospectively identified two cohorts of patients who had undergone prospective plasma sampling and clinical data collection: 16 patients with ER+/HER2− metastatic breast cancer (MBC) sampled within 6 months following metastatic diagnosis and 142 patients with stage 0 to III breast cancer who received curative-intent treatment with most sampled at surgery and 1 year postoperative. We performed whole-exome sequencing of tumors and designed individualized MRD tests, which we applied to serial cfDNA samples. Results: Our approach was 100-fold more sensitive than ddPCR when tracking 488 mutations, but most patients had fewer identifiable tumor mutations to track in cfDNA (median = 57; range = 2–346). Clinical sensitivity was 81% (n = 13/16) in newly diagnosed MBC, 23% (n = 7/30) at postoperative and 19% (n = 6/32) at 1 year in early-stage disease, and highest in patients with the most tumor mutations available to track. MRD detection at 1 year was strongly associated with distant recurrence [HR = 20.8; 95% confidence interval, 7.3–58.9]. Median lead time from first positive sample to recurrence was 18.9 months (range = 3.4–39.2 months). Conclusions: Tracking large numbers of individualized tumor mutations in cfDNA can improve MRD detection, but its sensitivity is driven by the number of tumor mutations available to track.
CORRELATIONS BETWEEN BLOOD PRESSURE AND MYOCARDIAL INJURY IN PATIENTS UNDERGOING BARIATRIC SURGERY
Authors: Austin Burns, Amelia Wallace, Carine Hamo, Roberta Florido, Justin B. Echouffo Tcheugui, Vijay Nambi, Gary Gerstenblith, Ron Hoogeveen, Christie M. Ballantyne, Elizabeth Selvin, Josef Coresh, Chiadi Ndumele
Journal: Journal of the American College of Cardiology (2020)
BYSTANDER PERFORMANCE DURING SIMULATED DRONE DELIVERY OF AN AED FOR MOCK OUT-OF-HOSPITAL CARDIAC ARREST
Authors: Monique A. Starks, Audrey L. Blewer, Edward Sharpe, Lee Van Vleet, Jennie Riley, Evan Arnold, Joseph Slattery, Anjni Joiner, Daniel M. Buckland, Jinny Ye, Daniel Mark
Journal: Journal of the American College of Cardiology (2020)
POOR CARDIOVASCULAR HEALTH IS ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS IN SUB-SAHARAN AFRICAN POPULATIONS: AN H3AFRICA AWI-GEN STUDY
Authors: Engelbert A. Nonterah, Abraham R. Oduro, Nigel J. Crowther, Michiel L. Bots, Osman Sankoh, Michele Ramsay, Diederick E. Grobbee, Kerstin Klipstein-Grobusch
Journal: Journal of the American College of Cardiology (2020)
A moncentric review of targeted therapy on overall survival in metastatic renal clear cell carcinoma.
Authors: Melanie Tadj, Valentin Arnoux, Mireille Mousseau, Jean Luc Descotes, Jean-Louis Quesada, Lamia Bensaadi, Mathieu Laramas
Journal: Journal of Clinical Oncology (2013)

e15593 Background: Anti-angiogenic treatment had radically modified therapeutic strategy in metastatic renal cell carcinoma (mRCC). This study is aimed to determine the overall survival (OS) improvement in clinical practice. Methods: Retrospective, monocentric and non-interventional study in mRCC diagnosed since 2000 with 2 cohorts of patients determined according to the first line treatment (targeted therapy or others treatment). Results: Between 1 January 2000 and 31 December 2010, 98 patients were included. The 2 cohorts were balanced with regard to baseline disease and demographic characteristics in particular for prognosis profiles distribution. As first line, 58 patients received targeted therapy whose 21% were treated by bevacizumab, 71% by sunitinib and 8% by temsirolimus. In non-targeted therapy cohort (n=40), 37.5% were treated by cytokines, 15% by cytotoxic chemotherapy or hormonal therapy. Patients treated with targeted therapy had a significantly longer median OS (30 months versus 13 months; p&lt;.003, log-rank test). The Hazard Ratio (HR) of death at 3 years was 0.53 (95% Confidence Interval, 0.33-0.85; p=.008, log-rank test). When adjusted to the prognosis profile, the HR of death was 0.43 (95%CI, 0.27-0.71). Conclusions: This retrospective study demonstrated the improvement of OS due to targeted treatments, for all prognostic risk groups. This result supported the complete change of care of mRCC patients with extension of therapeutic indications and efficient therapeutic lines.
PROGNOSTIC IMPACT OF AGE WITH SHORT-TERM VS. 12 MONTHS DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: A SUB-ANALYSIS OF THE REDUCE TRIAL
Authors: Monica Verdoia, Harry Suryapranata, Sander Damen, Cyril Camaro, Saman Rasoul, Houngbang Liew, Jawed Polad, Abdul Muhaimin Ahmad, Robaayah Zambahari, Jacques Lalmand, R.j. van der Schaaf, Tian Hai Koh, Frank Timmermans, D. Dilling-Boer, Leo Veenstra, Arnoud van't Hof, Swl Lee, Vincent Roolvink, Erik Ligtenberg, Sonja Postma, Evelien Kolkman, Marc Brouwer, Dariusz Dudek, Elvin Kedhi, Giuseppe De Luca
Journal: Journal of the American College of Cardiology (2020)
Antitumor activity of nab-paclitaxel and gemcitabine in resectable pancreatic cancer.
Authors: Rafael Alvarez-Gallego, Antonio Cubillo, Jesus Rodriguez-Pascual, Yolanda Quijano, Emilio De Vicente, Lina García, Fernando López-Ríos, Carlos Plaza, Elena García-García, María Pia Morelli, Manuel Hidalgo
Journal: Journal of Clinical Oncology (2012)

4040 Background: Nab-paclitaxel in combination with gemcitabine has shown interesting clinical activity in patients with advanced pancreatic cancer (PDA) likely related to its ability to eliminate pancreas cancer stroma. In this study we explore clinical and pathological effects of the combination in patients with operable PDA. Methods: Patients with resectable o borderline resectable pancreatic cancer were treated with gemcitabine(1000mg/m2 days 1, 8 and 15) and nab-paclitaxel(125mg/m 2 days 1, 8 and 15) for two cycles prior to surgery. Response was assessed by FDG-PET, CA199 levels and elastography, an EUS-based non invasive assessment of tumor stroma. Results: 16 patients were included into the study. 2 patients (12.5%) showed a progression disease (both with hepatic metastases) and were not operated. Median value for PET SUVmax decreased from 7,1 pre-treatment to 4,6 post-treatment(p=0.004), including 7(50%) of patients with a partial metabolic response and the mean CA199 decreased from 2654 to 52(p=0.02) with 43% patients having a more that 75 % decrement in tumor marker. The elastography ratio value diminished from 36 pre-treatment to 18 post-treatment(p=0.003) and correlated with improvement in SUVmax(p=0.04) and CA199 response(p=0,07). Grade 3-4 toxicities were neutropenia in 18% (none febrile neutropenia), thrombocytopenia in 12.5 and 6.2% transaminase elevation. So far 9 patients have been operated and in 8(89%) a complete resection (R0) was achieved. 1 patient had a complete pathological response and 4 patients had near complete responses with only a few(&lt; 5%) residual tumor. In-depth analysis of stromal composition after treatment showed, compared to a series of 10 cases untreated and treated with conventional chemoradiation, decreased myofibroblast content, increase vessel density and distorted collagen fibers. Conclusions: Neoadjuvant treatment with gemcitabine plus nab-paclitaxel is feasible and results in significant clinical activity. Non-invasive elastography appears and attractive method to monitor tumor response. The rate of pathological responses and R0 resections in substantial for this setting. Biological studies of resected specimens show unique effects in tumor stroma.
Factors That Affect Adequacy of Colon Cleansing for Colonoscopy in Hospitalized Patients
Authors: Lorenzo Fuccio, Leonardo Frazzoni, Cristiano Spada, Alessandro Mussetto, Carlo Fabbri, Mauro Manno, Giovanni Aragona, Rocco Maurizio Zagari, Emanuele Rondonotti, Gianpiero Manes, Pietro Occhipinti, Sergio Cadoni, Franco Bazzoli, Cesare Hassan, Franco Radaelli, Liboria Laterza, Luigina Vanessa Alemanni, Francesco Buttitta, Giovanna Cirota, Anna Cominardi, Giovanna Impellizzeri, Marina La Marca, Giovanni Marasco, Flavio Metelli, Chiara Pierantoni, Vito Sansone, Giacomo Tamanini, Paola Cesaro, Stefania Piccirelli, Valentina Feletti, Omero Triossi, Rosario Arena, Cecilia Binda, Gianni Nicolini, Monica Sbrancia, Margherita Trebbi, Biagio Cuffari, Paola Soriani, Giuseppe Comparato, Gian Maria Prati, Raffaella Reati, Cristina della Corte, Mauro Liggi, Donatella Mura
Journal: Clinical Gastroenterology and Hepatology (2020)
High-resolution modeling of the selection on local mRNA folding strength in coding sequences across the tree of life
Authors: Michael Peeri, Tamir Tuller
Journal: Genome biology (2020)

Abstract Background mRNA can form local secondary structure within the protein-coding sequence, and the strength of this structure is thought to influence gene expression regulation. Previous studies suggest that secondary structure strength may be maintained under selection, but the details of this phenomenon are not well understood. Results We perform a comprehensive study of the selection on local mRNA folding strengths considering variation between species across the tree of life. We show for the first time that local folding strength selection tends to follow a conserved characteristic profile in most phyla, with selection for weak folding at the two ends of the coding region and for strong folding elsewhere in the coding sequence, with an additional peak of selection for strong folding located downstream of the start codon. The strength of this pattern varies between species and organism groups, and we highlight contradicting cases. To better understand the underlying evolutionary process, we show that selection strengths in the different regions are strongly correlated, and report four factors which have a clear predictive effect on local mRNA folding selection within the coding sequence in different species. Conclusions The correlations observed between selection for local secondary structure strength in the different regions and with the four genomic and environmental factors suggest that they are shaped by the same evolutionary process throughout the coding sequence, and might be maintained under direct selection related to optimization of gene expression and specifically translation regulation.
How to design a study to evaluate therapeutic drug monitoring in infectious diseases?
Authors: A.-G. Märtson, M.G.G. Sturkenboom, J. Stojanova, D. Cattaneo, W. Hope, D. Marriott, A.E. Patanwala, C.A. Peloquin, S.G. Wicha, T.S. van der Werf, T. Tängdén, J.A. Roberts, M.N. Neely, J.-W.C. Alffenaar
Journal: Clinical Microbiology and Infection (2020)
THE LDL/APOLIPOPROTEIN B RATIO, AN INDEX FOR LDL PARTICLE SIZE, IS A STRONG PREDICTOR FOR NEOINTIMAL CHARACTERISTICS AND IN-STENT RESTENOSIS AFTER EVEROLIMUS-ELUTING STENT IMPLANTATION
Authors: Naotaka Akutsu, Fukamachi Daisuke, Yasunari Ebuchi, Arai Riku, Suguru Migita, Tomoyuki Morikawa, Takehiro Tamaki, Keisuke Kojima, Nobuhiro Murata, Toshihiko Nishida, Mitsumasa Sudo, Daisuke Kitano, Yasuo Okumura
Journal: Journal of the American College of Cardiology (2020)
Clinical Role of CA125 in Worsening Heart Failure
Authors: Julio Núñez, Antoni Bayés-Genís, Elena Revuelta-López, Jozine M. ter Maaten, Gema Miñana, Jaume Barallat, Adriana Cserkóová, Vicent Bodi, Agustín Fernández-Cisnal, Eduardo Núñez, Juan Sanchis, Chim Lang, Leong L. Ng, Marco Metra, Adriaan A. Voors
Journal: JACC Heart Failure (2020)
Abstract 11427: Cardiac-specific Abrogation of NF-kB Activation Ameliorates Pressure Overload-induced Left Ventricular Hypertrophy and Dysfunction
Authors: Guangming Cheng, Lin Zhao, Magdy Girgis, Arash Davani, Yanjuan Yang, Jeryl Hauptman, Buddhadeb Dawn
Journal: Circulation (2019)

Introduction: Nuclear factor-kappaB (NF-kB) is a pleiotropic stress-responsive transcription factor that regulates the expression of multiple genes, including those that govern inflammatory respons...
THE INCIDENCE, MAGNITUDE AND CAUSE OF IMPEDED-BY-STENT PHENOMENON AFTER IMPLANTING TWO-LINKED DESIGN NEW GENERATION STENTS
Authors: Yutaka Tadano, Junichi Kotani, Yoshifumi Kashima, Tomohiko Watanabe, Takuro Sugie, Daitaro Kanno, Tsutomu Fujita
Journal: Journal of the American College of Cardiology (2020)
ELIGIBILITY AND COST OF LOW-DOSE RIVAROXABAN BASED ON COMPASS TRIAL: INSIGHTS FROM THE VETERANS AFFAIRS HEALTHCARE SYSTEM
Authors: Akash Kataruka, Dhruv Mahtta, Julia M. Akeroyd, Ravi Hira, Dhruv Kazi, John A. Spertus, Deepak Bhatt, Laura Petersen, Christie M. Ballantyne, Salim S. Virani, Michael E. DeBakey
Journal: Journal of the American College of Cardiology (2020)